<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: To characterize clinical manifestations, course and laboratory signs of <z:hpo ids='HP_0000112'>nephropathy</z:hpo> in <z:e sem="disease" ids="C0409980" disease_type="Disease or Syndrome" abbrv="">primary antiphospholipid syndrome</z:e> (<z:chebi fb="61" ids="27565">PAS</z:chebi>) </plain></SENT>
<SENT sid="1" pm="."><plain>MATERIAL AND METHODS: 6 patients with <z:chebi fb="61" ids="27565">PAS</z:chebi> and renal affection were observed for 10 years since 1991 </plain></SENT>
<SENT sid="2" pm="."><plain>They were examined for anticardiolipin antibodies and/or <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>Renal tissue was studied morphologically in one patient </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: In <z:hpo ids='HP_0000001'>all</z:hpo> the patients renal damage manifested with arterial <z:hpo ids='HP_0000822'>hypertension</z:hpo> associated with isolated <z:hpo ids='HP_0000093'>proteinuria</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>The majority of the patients had <z:hpo ids='HP_0000082'>renal dysfunction</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> of them had elevated level of antibodies to <z:chebi fb="0" ids="28494">cardiolipin</z:chebi> primarily in combination with <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>Histological changes of renal tissue presented with <z:e sem="disease" ids="C0034155" disease_type="Disease or Syndrome" abbrv="">thrombotic microangiopathy</z:e> of glomerular and extraglomerular vessels, intimal proliferation and vascular wall thickening with occlusion of their lumen which combined with morphological indicators of <z:hpo ids='HP_0000097'>focal segmental glomerulosclerosis</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: The thrombotic process in the intrarenal vessels in <z:chebi fb="61" ids="27565">PAS</z:chebi> dictates the necessity to develop novel approaches to treatment of such patients </plain></SENT>
<SENT sid="9" pm="."><plain>In addition to immunodepressants the treatment should include indirect <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> and antiaggregants </plain></SENT>
</text></document>